Name | Value |
---|---|
Revenues | 0.0K |
Cost of Revenue | 5.3K |
Gross Profit | -5.3K |
Operating Expense | 3,305.0K |
Operating I/L | -3,305.0K |
Other Income/Expense | -0.5K |
Interest Income | 0.0K |
Pretax | -3,305.5K |
Income Tax Expense | -7.2K |
Net Income/Loss | -3,305.5K |
Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company specializing in the development of products for the treatment of neurodegenerative and psychiatric disorders. Their pipeline includes AL001, a Phase II clinical trial product delivering a therapeutic combination for Alzheimer's, bipolar disorder, PTSD, major depressive disorder, and other neurodegenerative and psychiatric disorders. Additionally, AL002, which completed the preclinical stage, uses a method employing a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the patient's immunological system to combat Alzheimer's disease.